AnaptysBio Inc
ANAB · NASDAQ
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
Market Data
Price
$62.33
+0.32 (+0.52%)
Market Cap$1.78B
P/E Ratio—
EPS$—
52W High$63.47
52W Low$15.32
Beta0.35
Data from Finnhub · Updated Mar 11, 2026